Pharmaceutical Technology

OCTOBER 25, 2022

The companies will jointly create a virtual patient engine for the drug candidates’ clinical translation. The partnership intends to address a 90% failure rate of new therapy candidates in clinical development, which is a key bottleneck of the pharmaceutical industry.

Development 246

Development Drugs In-Vivo Engineer 246

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

The Pharma Data

JANUARY 12, 2021

Working alongside KSQ will facilitate smart drug discovery and development of what we hope will be transformative new therapies for patients with intractable forms of cancer.”. In addition, KSQ will be eligible for additional option payments along with development and commercialization milestone payments. sales for that product.

Development 52

Development Research In-Vivo Genome 52

The Pharma Data

DECEMBER 10, 2020

Many people who have been exposed to the “common cold” potentially develop adenovirus immunity: the immune system often attacks and disables these first-generation vaccines before they can activate the immune response to attack the SARS-CoV-2 virus. This blocking of viral replication was observed in both the lung and nasal passages.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JANUARY 4, 2021

Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. PD-1 has always been a challenge for CAR-T development. “We believe Prof. About PD-1 Check-point inhibition. Dr. Barber is a tumor immunologist.

In-Vivo 40

In-Vivo Development Immune Response Big Data 40

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

OCTOBER 15, 2020

The award honors McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus. Additionally, Sarah Haecker Meeks, joined the Company as vice president of Business Development and Steve Nardi joined as vice president of Manufacturing and Engineering Operations.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52